[Report] The Global Antivirals Market - R&D Pipelines, Market Analysis and Competitive Landscape TOC

1 EXECUTIVE SUMMARY

2 INTRODUCTION TO INFECTIOUS DISEASES

2.1 Cytomegalovirus (CMV)
2.2 Hepatitis B virus (HBV)
2.3 Hepatitis C Virus (HCV)
2.4 Herpes Simplex Virus (HSV)
2.5 Human Immunodeficiency Virus (HIV)
2.6 Influenza (Flu)
2.7 Respiratory Syncytial Virus (RSV)

3 PATIENT DEMOGRAPHICS

3.1 Cytomegalovirus Patient Statistics
3.2 Hepatitis B Patient Statistics
3.3 Hepatitis C Patient Statistics
3.4 Herpes Simplex Patient Statistics
3.5 Human Immunodeficiency Patient Statistics
3.6 Influenza Patient Statistics
3.7 Respiratory Syncytial Patient Statistics

4 KEY DRIVERS

4.1 Drug Resistance
4.2 Cross-Resistance
4.3 New treatments
4.4 Combination therapy
4.5 Improvements in diagnosis
4.6 Vaccines
4.7 Potential for clinical success
4.8 Indirect cost associated with infectious diseases

5 KEY RESISTORS

5.1 Cost-benefit of prophylactic therapy or antiviral therapy
5.2 Treatment availability
5.3 Patient demographics
5.4 Generics
5.5 Curative Therapies and Vaccines
5.6 Diagnosis

6 THE MARKET

6.1 The Global Anti-Infective Market
6.2 Market Segments
6.3 Global Anti-Viral Market
- 6.3.1 Antiretroviral Agents
- 6.3.2 Hepatitis Antiviral Agents
- 6.3.3 Other Antiviral Agents
6.4 The Major Players
- 6.4.1 Antiviral Major Players in 2006
- 6.4.2 Antiviral Major Players in 2012
6.5 Market Trends
- 6.5.1 Antiretroviral Agents by 2012
- 6.5.2 Hepatitis Agents by 2012
- 6.5.3 Other Antiviral Agents by 2012

7 LEADING DRUG CLASSES

7.1 Antisense
7.2 DNA Polymerase Inhibitors
7.3 Interferons
7.4 Fusion Inhibitors
7.5 Neuraminidase Inhibitors
7.6 Reverse Transcriptase Inhibitors
7.7 RNA Polymerase Inhibitors
7.8 Protease Inhibitors
7.9 Uncoating Inhibitors

8 LEADING BRANDS

8.1 Antisense
- 8.1.1 Vitravene (Novartis/[ISIS Pharmaceuticals])
- 8.1.2 Antisense Sales Forecasts
8.2 DNA Polymerase Inhibitors
- 8.2.1 DNA Polymerase Inhibitors Forecasts
8.3 RNA Polymerase Inhibitors
- 8.3.1 RNA Polymerase Inhibitors Forecasts
8.4 Fusion Inhibitors
- 8.4.1 Fuzeon (Roche/Trimeris)
  - 8.4.1.1 Fuzeon' s tolerability profile
  - 8.4.1.2 Fuzeon' s Needle-Free Device
- 8.4.2 Fusion Inhibitor Sales Forecasts
8.5 Inteferons
- 8.5.1 Interferon Sales Forecasts
8.6 Monoclonal Antibodies
- 8.6.1 Synagis (MedImmune)
- 8.6.2 Monoclonal Antibody Sales Forecasts
8.7 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 8.7.1 NNRTI Sales Forecasts
8.8 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 8.8.1 NRTIs Combination Franchises
- 8.8.2 NRTI Sales Forecasts
8.9 Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
- 8.9.1 NtRTI Sales Forecasts
8.10 Protease Inhibitors
- 8.10.1 PI Sales Forecasts
8.11 Neuraminidase Inhibitors (NIs)
- 8.11.1 Neuraminidase Inhibitors Sales Forecasts
8.12 Global Anti-Viral Sales Forecasts

9 FUTURE BRANDS

9.1 Attachment, Entry and Fusion Inhibitors
- 9.1.1 AMD070 (AnorMed/Genzyme)
- 9.1.2 BMS-488043 (Bristol-Myers Squibb)
- 9.1.3 FP-21399 (EMD Lexigen)
- 9.1.4 HIV Fusion Inhibitor (Panacos)
- 9.1.5 Maraviroc (Pfizer)
9.1. Ongoing pivotal Phase II/III Maraviroc trails
- 9.1.6 PRO 140 (Progenics)
- 9.1.7 SP01A (Samaritan Pharmaceuticals)
- 9.1.8 TNX-355 (Tanox/Biogen Idec)
- 9.1.9 T-1249 / TRI-1144/TRI-999 (Roche/Trimeris)
- 9.1.10 Vicriviroc (Schering-Plough)
9.1. Safety Profile of Vicriviroc
9.2 Integrase Inhibitors
- 9.2.1 GS 9137 (Gilead Sciences/[Japan Tobacco])
- 9.2.2 MK-0518 (Merck & Co)
  - 9.2.2.1 Safety Profile of MK-0518
9.3 Interferons
- 9.3.1 Albuferon (Novartis/Human Genome Sciences)
  - 9.3.1.1 Pivotal ACHIEVE Trial results
9.4 Maturation Inhibitors
- 9.4.1 Bevirimat (Panacos)
  - 9.4.1.1 Mixed Phase II results with Bevirimat
9.5 Non-Nucleoside Reverse Transcriptase Inhibitors
- 9.5.1 BILR 355 BS (Boehringer Ingelheim)
- 9.5.2 Calanolide A (Advanced Life Sciences)
- 9.5.3 Etravirine (Johnson & Johnson/[Tibotec])
  - 9.5.3.1 Etravirine discontinued in treatment-naïve patients
  - 9.5.3.2 Etravirines safety profile
  - 9.5.3.3 Ongoing pivotal etravine trials
- 9.5.4 UK-453,061 (Pfizer)
9.6 Nucleoside Reverse Transcriptase Inhibitors
- 9.6.1 Alovudine & Fosalvudine (Medivir)
- 9.6.2 Apricitabine (Avexa/Shire Pharmaceuticals)
  - 9.6.2.1 Ongoing Pivotal Apricitabine Trials
- 9.6.3 Dexelvutabine (Pharmasset)
- 9.6.4 Elvucitabine (Achillion Pharmaceuticals)
- 9.6.5 Racivir (Pharmasset Inc)
  - 9.6.5.1 Racivir' s mutation profile
9.7 Protease Inhibitors
- 9.7.1 PPL-100 (Ambrilla Biopharma/Merck & Co.)
9.8 NS3 Protease Inhibitors
- 9.8.1 SCH 503034 (Schering-Plough)
  - 9.8.1.1 SCH 503034 safety profile
  - 9.8.1.2 Ongoing pivotal SCH 503034 trials
- 9.8.2 Telaprevir (Vertex/ Johnson & Johnson/Mitsubishi)
  - 9.8.2.1 Telaprevir' s Tolerability Profile
  - 9.8.2.2 Ongoing Pivotal Telaprevir Trials
9.9 Polymerase Inhibitors
- 9.9.1 R1626 (Roche)
- 9.9.2 R7128 (Roche/[Pharmasset])
- 9.9.3 Valopicitabine (Idenix Pharmaceuticals/Novartis)
- 9.9.4 Valtorcitabine (Index Pharmaceuticals)
9.10 Global Sales Forecasts for New Anti-Viral Agents
9.11 The Future of the Antiviral Market

10 APPENDIX 1 - PHARMACEUTICAL COMPANIES

Abbott Laboratories
AstraZeneca AB
Boehringer Ingelheim Corporation
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Johnson & Johnson,
Merck & Co Inc
Novartis International AG
Pfizer Inc
Roche

11 APPENDIX 2 - BIOTECHNOLOGY AND BIOPHARMACEUTICAL COMPANY PROFILES

11.1 Achillon Pharmaceuticals
11.2 Agouron Pharmaceuticals (A Pfizer subsidiary)
11.2 Genzyme
11.3 ISIS Pharmaceuticals
11.4 MEDIVIR AB
11.5 Panacos
11.6 Pharmasset, Inc.
11.7 Progenics Pharmaceuticals, Inc.
11.8 Tanox
11.9 Tibotec
11.10 Trimeris, Inc.
11.11 Vertex Pharmaceuticals

12 APPENDIX 3

12.1 Bibliography

TABLES

Table 2.1: Infectious Disease Leading Worldwide Health Burden
Table 3.1: Worldwide Prevalence of HCV
Table 4.1. Potential for clinical success
Table 6.1: Historical Sales of 30 Leading Anti-infective Brands US$ million (2001-2005)
Table 8.1. Infectious Agent Treatment Options
Table 8.2: Sales Forecasts of Antisense Products US$m 2005A - 2012E
Table 8.3: Comparison of the Leading DNA Polymerase Inhibitor Brands for the Treatment of CMV
Table 8.4: Comparison of the Leading DNA Polymerase Inhibitor Brands for the Treatment of HSV
Table 8.5: Sales Forecasts of DNA Polymerase Inhibitors (US$m) 2005A - 2012E
Table 8.6: Sales Forecasts of RNA Polymerase Inhibitors 2005A - 2012E
Table 8.7: Sales Forecasts of Fusion Inhibitors (US$m) 2005A - 2012E
Table 8.8: Comparison of the Leading Interferon Monotherapies Approved for Hepatitis
Table 8.9: Comparison of the Leading Interferon Combination Therapies Approved for Hepatitis
Table 8.10: Sales Forecasts of Interferons (US$m) 2005A - 2012E
Table 8.11: Sales Forecasts of Monoclonal Antibodies (US$m) 2005A - 2012E
Table 8.12: Comparison of the Leading NNRTIs
Table 8.13: Sales Forecasts of NNRTIs (US$m) 2005A - 2012E
Table 8.14: Comparison of the Leading NRTI Approved for HBV
Table 8.15: Comparison of the Leading NRTIs Approved for HIV Monotherapy
Table 8.16: Comparison of the Leading NRTI Combination Therapies Approved for HIV
Table 8.17: Sales Forecasts of NRTIs (US$m) 2005A - 2012E
Table 8.18: Comparison of the Leading NtRTIs Brands
Table 8.19: Sales Forecasts of NtRTIs (US$m) 2005A - 2012E
Table 8.20: Comparison of the Leading PI Brands - Single Agents
Table 8.21: The Leading Combination PI Brand
Table 8.22: Sales Forecasts of PIs (US$m) 2005A - 2012E
Table 8.23: Leading NIs Approved for Influenza
Table 8.24: Sales Forecasts of NIs (US$m) 2005A - 2012E
Table 8.25: Sales Summary of Antiviral Agents (US$m) 2005A - 2012E
Table 9.1 Reduction of Viral Load Following Treatment with GS 0137
Table 9.2: Reduction of Viral Load Following Treatment with TNC125
Table 9.3: Sales Summary of New AntiViral Agents (US$m) 2005A - 2012E
Table 9.4 Sales Summary of New Antiviral Agents (US$m) 2005A - 2012E

FIGURES

Figure 2.1 Schematic of influenza virus
Figure 3.1 Geographic Distribution of Chronic HBV Infection
Figure 6.1 Global Anti-Infective Market US$66.5 bn (2006)
Figure 6.2 Global Anti-Infective Market US$100 bn (2015)
Figure 6.3 Antiretroviral Agents US$9.7 bn - Drug Class Split (2006)
Figure 6.4 Hepatitis Antiviral Agents US$3.8 bn - Drug Class Split (2006)
Figure 6.5 Other Antiviral Agents US$6.4 bn - Therapy Class Split (2006)
Figure 6.6 The Major Players (2006)
Figure 6.7 The Major Players (2012)
Figure 6.8 The Global Antiviral Market (2012)
Figure 6.9 Antiretroviral Agents US$12.6 bn - Drug Class Split (2012)
Figure 6.10 Antiviral Agents US$5.5 bn - Drug Class Split (2012)
Figure 6.11 Other Antiviral Agents US$5.6 bn - Therapy Class Split (2012)
Figure 7.1 Site of Action of Leading Antiviral Agents
Figure 8.1 Clinical Efficacy in TORO 1 & 2 Studies
Figure 8.2 Global HCV Therapy
Figure 9.1 Structure of Maraviroc
Figure 9.2 Clinical Efficacy of TNX-355
Figure 9.3 Virologic Response to TNX-355
Figure 9.4 Pharmacokinetics of TRI-1144 in Rat Models
Figure 9.5 Pharmokinetics of TRI-999 formulations in Rat Models
Figure 9.6 Clinical Efficacy of Vicriviroc
Figure 9.7 Clinical Efficacy of Vicriviroc in Sub Populations
Figure 9.8 Clinical Efficacy of MK0518
Figure 9.9 Schematic of Albuferon' s Structure
Figure 9.10 Phase II Pharmacokinetic Profile of Albuferon
Figure 9.11 (+)-Calanolide A Structure
Figure 9.12 Clinical Efficacy of Racivir
Figure 9.13 Clinical Efficacy of Racivir
Figure 9.14 Phase I Clinical Efficacy of Racivir
Figure 9.15 Clinical Efficacy of Valopicitabine
Figure 9.16 Clinical Efficacy of Valopicitabine
Figure 11.1 Medivir AB Pipeline
Figure 11.2 Pharmassett Pipeline
Figure 11.3 Progenics Pipeline
Figure 11.4 Tanox Pipeline
Figure 11.5 Vertex Pipeline

The Global Antivirals Market - R&D Pipelines, Market Analysis and Competitive Landscape

Table of Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION TO INFECTIOUS DISEASES

3 PATIENT DEMOGRAPHICS

4 KEY DRIVERS

5 KEY RESISTORS

6 THE MARKET

7 LEADING DRUG CLASSES

8 LEADING BRANDS

9 FUTURE BRANDS

10 APPENDIX 1 - PHARMACEUTICAL COMPANIES

11 APPENDIX 2 - BIOTECHNOLOGY AND BIOPHARMACEUTICAL COMPANY PROFILES

12 APPENDIX 3

TABLES

FIGURES